Cti Biopharma Stock News

Investors need to pay close attention to CTI BioPharma (CTIC) stock based on the movements in the options market lately.

Investors need to pay close attention to CTI BioPharma (CTIC) stock based on the movements in the options market lately.

Squarepoint Ops LLC reduced its stake in shares of CTI BioPharma Corp. (NASDAQ:CTIC) by 63.4% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 72,325 shares of the biopharmaceutical companys stock after selling 125,186 shares during the period. Squarepoint Ops LLCs holdings in CTI BioPharma were worth $181,000 as of its most recent SEC []

The trading price of CTI BioPharma Corp. (NASDAQ:CTIC) closed lower on Tuesday, November 23, closing at $2.35, -2.49% lower than its previous close. >> 7 Top Picks for the Post-Pandemic Economy

Equities research analysts expect CTI BioPharma Corp. (NASDAQ:CTIC) to announce sales of $27.55 million for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for CTI BioPharmas earnings. The lowest sales estimate is $3.00 million and the highest is $52.10 million. The company is expected to issue its next earnings report on []

JMP Securities restated their buy rating on shares of CTI BioPharma (NASDAQ:CTIC) in a research note released on Wednesday, TipRanks reports. The firm currently has a $4.00 price objective on the biopharmaceutical companys stock. Other research analysts also recently issued reports about the company. Zacks Investment Research upgraded CTI BioPharma from a sell rating to []

JMP Securities reissued their buy rating on shares of CTI BioPharma (NASDAQ:CTIC) in a research note released on Wednesday, TipRanks reports. The firm currently has a $4.00 price objective on the biopharmaceutical companys stock. CTIC has been the topic of several other research reports. BTIG Research began coverage on CTI BioPharma in a research report []

Brookline Capital Management reiterated their buy rating on shares of CTI BioPharma (NASDAQ:CTIC) in a report issued on Monday, Zacks.com reports. Several other brokerages also recently commented on CTIC. JMP Securities restated a buy rating and set a $4.00 price objective on shares of CTI BioPharma in a research report on Tuesday, August 31st. BTIG []

CTI BioPharma Corp (NASDAQ: CTIC) has announced topline results from the PRE-VENT trial of pacritinib in hospitalized COVID-19 patients. The final PRE-VENT analysis was conducted following the rand

SEATTLE, Oct. 1, 2021 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced topline results from the PRE-VENT trial (NCT04404361) of pacritinib in hospitalized patients with severe COVID

SEATTLE, Sept. 8, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards

These penny stocks could be in focus as we turn the page on a new month. The post 5 Penny Stocks To Watch For September With Upcoming Events appeared first on Penny Stocks to Buy, Picks, News and Info

The stock price of CTI BioPharma Corp. (Nasdaq: CTIC) increased by over 5% pre-market. This is why it happened.

SEATTLE, Aug. 24, 2021 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced the appointment of Diane Parks to its Board of Directors. Ms. Parks has overseen the launch of numerous hemat

CTI BioPharma Corp. (CTIC) CEO Adam Craig on Q2 2021 Results - Earnings Call Transcript